{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T03:43:55Z","timestamp":1792727035989,"version":"4.5.0"},"reference-count":200,"publisher":"Elsevier BV","issue":"2","content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2013,5]]},"DOI":"10.1016\/j.antiviral.2013.03.017","type":"journal-article","created":{"date-parts":[[2013,3,28]],"date-time":"2013-03-28T03:17:50Z","timestamp":1364440670000},"page":"158-170","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":114,"title":["Entry inhibitors and their use in the treatment of HIV-1 infection"],"prefix":"10.1016","volume":"98","author":[{"given":"Aiman A.","family":"Haqqani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John C.","family":"Tilton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2013.03.017_b0005","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1126\/science.272.5270.1955","article-title":"CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1","volume":"272","author":"Alkhatib","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.antiviral.2013.03.017_b0010","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1006\/viro.1997.8673","article-title":"HIV-1 coreceptor activity of CCR5 and its inhibition by chemokines: independence from G protein signaling and importance of coreceptor downmodulation","volume":"234","author":"Alkhatib","year":"1997","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2013.03.017_b0015","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1182\/blood-2010-09-309591","article-title":"Evidence for the cure of HIV infection by CCR5\u039432\/\u039432 stem cell transplantation","volume":"117","author":"Allers","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.antiviral.2013.03.017_b0020","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/nature11724","article-title":"CCR5 is a receptor for Staphylococcus aureus leukotoxin ED","volume":"493","author":"Alonzo","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2013.03.017_b0025","doi-asserted-by":"crossref","first-page":"5318","DOI":"10.1073\/pnas.0811713106","article-title":"Resistance to CCR5 inhibitors caused by sequence changes in the fusion peptide of HIV-1 gp41","volume":"106","author":"Anastassopoulou","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.antiviral.2013.03.017_b0030","doi-asserted-by":"crossref","first-page":"e79","DOI":"10.1371\/journal.ppat.0030079","article-title":"Escape of HIV-1 from a small molecule CCR5 inhibitor is not associated with a fitness loss","volume":"3","author":"Anastassopoulou","year":"2007","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.antiviral.2013.03.017_b0035","doi-asserted-by":"crossref","first-page":"e49602","DOI":"10.1371\/journal.pone.0049602","article-title":"Use of four next-generation sequencing platforms to determine HIV-1 coreceptor tropism","volume":"7","author":"Archer","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.antiviral.2013.03.017_b0040","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/ni1566","article-title":"HIV-1 envelope protein binds to and signals through integrin alpha4beta7, the gut mucosal homing receptor for peripheral T cells","volume":"9","author":"Arthos","year":"2008","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.antiviral.2013.03.017_b0045","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1074\/jbc.M708325200","article-title":"Conformational rearrangement within the soluble domains of the CD4 receptor is ligand-specific","volume":"283","author":"Ashish","year":"2008","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.antiviral.2013.03.017_b0050","doi-asserted-by":"crossref","first-page":"e21535","DOI":"10.1371\/journal.pone.0021535","article-title":"Impact of the HIV-1 env genetic context outside HR1-HR2 on resistance to the fusion inhibitor enfuvirtide and viral infectivity in clinical isolates","volume":"6","author":"Baatz","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.antiviral.2013.03.017_b0055","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1128\/AAC.01079-06","article-title":"Isolation and characterization of human immunodeficiency virus type 1 resistant to the small-molecule CCR5 antagonist TAK-652","volume":"51","author":"Baba","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2013.03.017_b0060","doi-asserted-by":"crossref","first-page":"10791","DOI":"10.1128\/JVI.76.21.10791-10800.2002","article-title":"Identification of conserved and variable structures in the human immunodeficiency virus gp120 glycoprotein of importance for CXCR4 binding","volume":"76","author":"Basmaciogullari","year":"2002","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2013.03.017_b0065","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.virol.2012.02.006","article-title":"V3 determinants of HIV-1 escape from the CCR5 inhibitors Maraviroc and Vicriviroc","volume":"427","author":"Berro","year":"2012","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2013.03.017_b0070","doi-asserted-by":"crossref","DOI":"10.1093\/jac\/dks539","article-title":"Switching the third drug of antiretroviral therapy to maraviroc in aviraemic subjects: a pilot, prospective, randomized clinical trial","author":"Bonjoch","year":"2013","journal-title":"J. Antimicrob. Chemother"},{"key":"10.1016\/j.antiviral.2013.03.017_b0075","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s15010-011-0223-4","article-title":"Short-term additional enfuvirtide therapy is associated with a greater immunological recovery in HIV very late presenters: a controlled pilot study","volume":"40","author":"Bonora","year":"2012","journal-title":"Infection"},{"key":"10.1016\/j.antiviral.2013.03.017_b0080","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1093\/jac\/dkr219","article-title":"Pharmacokinetics of the raltegravir\/maraviroc\/etravirine combination","volume":"66","author":"Calcagno","year":"2011","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.antiviral.2013.03.017_b0085","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.jinf.2012.05.008","article-title":"Vicriviroc plus optimized background therapy for treatment-experienced subjects with CCR5 HIV-1 infection: final results of two randomized phase III trials","volume":"65","author":"Caseiro","year":"2012","journal-title":"J. Infect."},{"key":"10.1016\/j.antiviral.2013.03.017_b0090","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1097\/QAI.0b013e31818c953f","article-title":"Chemokine analogues show suitable stability for development as microbicides","volume":"49","author":"Cerini","year":"2008","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.antiviral.2013.03.017_b0095","doi-asserted-by":"crossref","first-page":"6598","DOI":"10.1128\/JVI.73.8.6598-6609.1999","article-title":"Mutagenesis of CXCR4 identifies important domains for human immunodeficiency virus type 1 X4 isolate envelope-mediated membrane fusion and virus entry and reveals cryptic coreceptor activity for R5 isolates","volume":"73","author":"Chabot","year":"1999","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2013.03.017_b0100","doi-asserted-by":"crossref","first-page":"15613","DOI":"10.1073\/pnas.95.26.15613","article-title":"Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target","volume":"95","author":"Chan","year":"1998","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.antiviral.2013.03.017_b0105","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0092-8674(00)80205-6","article-title":"Core structure of gp41 from the HIV envelope glycoprotein","volume":"89","author":"Chan","year":"1997","journal-title":"Cell"},{"key":"10.1016\/j.antiviral.2013.03.017_b0110","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1093\/jac\/dks067","article-title":"Prevalence of subtype-related polymorphisms associated with in vitro resistance to attachment inhibitor BMS-626529 in HIV-1 \u201cnon-B-\u201dinfected patients","volume":"67","author":"Charpentier","year":"2012","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.antiviral.2013.03.017_b0115","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1038\/nature03327","article-title":"Structure of an unliganded simian immunodeficiency virus gp120 core","volume":"433","author":"Chen","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2013.03.017_b0120","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/S0092-8674(00)81313-6","article-title":"The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates","volume":"85","author":"Choe","year":"1996","journal-title":"Cell"},{"key":"10.1016\/j.antiviral.2013.03.017_b0125","doi-asserted-by":"crossref","first-page":"20877","DOI":"10.1073\/pnas.0911796106","article-title":"The integrin alpha4beta7 forms a complex with cell-surface CD4 and defines a T-cell subset that is highly susceptible to infection by HIV-1","volume":"106","author":"Cicala","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.antiviral.2013.03.017_b0130","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1126\/science.270.5243.1811","article-title":"Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells","volume":"270","author":"Cocchi","year":"1995","journal-title":"Science"},{"key":"10.1016\/j.antiviral.2013.03.017_b0135","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1084\/jem.185.4.621","article-title":"Change in coreceptor use coreceptor use correlates with disease progression in HIV-1\u2013infected individuals","volume":"185","author":"Connor","year":"1997","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.antiviral.2013.03.017_b0140","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1097\/QAI.0b013e318273015f","article-title":"Maraviroc intensification of stable antiviral therapy in HIV-1-infected patients with poor immune restoration: MARIMUNO-ANRS 145 study","volume":"61","author":"Cuzin","year":"2012","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.antiviral.2013.03.017_b0145","doi-asserted-by":"crossref","first-page":"6574","DOI":"10.1073\/pnas.87.17.6574","article-title":"High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates","volume":"87","author":"Daar","year":"1990","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.antiviral.2013.03.017_b0150","doi-asserted-by":"crossref","first-page":"882","DOI":"10.7326\/0003-4819-127-10-199711150-00004","article-title":"Association between CCR5 genotype and the clinical course of HIV-1 infection","volume":"127","author":"de Roda Husman","year":"1997","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.antiviral.2013.03.017_b0155","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1126\/science.273.5283.1856","volume":"273","author":"Dean","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.antiviral.2013.03.017_b0160","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1086\/510531","article-title":"Interruption of enfuvirtide in HIV-1 infected adults with incomplete viral suppression on an enfuvirtide-based regimen","volume":"195","author":"Deeks","year":"2007","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2013.03.017_b0165","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/381661a0","article-title":"Identification of a major co-receptor for primary isolates of HIV-1","volume":"381","author":"Deng","year":"1996","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2013.03.017_b0170","doi-asserted-by":"crossref","first-page":"8358","DOI":"10.1128\/JVI.74.18.8358-8367.2000","article-title":"Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120","volume":"74","author":"Derdeyn","year":"2000","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2013.03.017_b0175","doi-asserted-by":"crossref","first-page":"309","DOI":"10.3390\/v4020309","article-title":"Novel approaches to inhibit HIV entry","volume":"4","author":"Didigu","year":"2012","journal-title":"Viruses"},{"key":"10.1016\/j.antiviral.2013.03.017_b0180","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/j.cyto.2012.12.013","article-title":"Maraviroc reduces cytokine expression and secretion in human adipose cells without altering adipogenic differentiation","volume":"61","author":"D\u00edaz-Delf\u00edn","year":"2013","journal-title":"Cytokine"},{"key":"10.1016\/j.antiviral.2013.03.017_b0185","doi-asserted-by":"crossref","first-page":"2752","DOI":"10.1128\/JVI.73.4.2752-2761.1999","article-title":"Identification of CXCR4 domains that support coreceptor and chemokine receptor functions","volume":"73","author":"Doranz","year":"1999","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2013.03.017_b0190","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S0092-8674(00)81314-8","article-title":"A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors","volume":"85","author":"Doranz","year":"1996","journal-title":"Cell"},{"key":"10.1016\/j.antiviral.2013.03.017_b0195","doi-asserted-by":"crossref","first-page":"4721","DOI":"10.1128\/AAC.49.11.4721-4732.2005","article-title":"Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity","volume":"49","author":"Dorr","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2013.03.017_b0200","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/381667a0","article-title":"HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5","volume":"381","author":"Dragic","year":"1996","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2013.03.017_b0205","doi-asserted-by":"crossref","first-page":"5067","DOI":"10.1128\/JVI.00055-09","article-title":"Selection of a simian-human immunodeficiency virus strain resistant to a vaginal microbicide in macaques","volume":"83","author":"Dudley","year":"2009","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2013.03.017_b0210","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1128\/JVI.72.2.1160-1164.1998","article-title":"A tyrosine-rich region in the N terminus of CCR5 is important for human immunodeficiency virus type 1 entry and mediates an association between gp120 and CCR5","volume":"72","author":"Farzan","year":"1998","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2013.03.017_b0215","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/S0092-8674(00)80577-2","article-title":"Tyrosine sulfation of the amino terminus of CCR5 facilitates HIV-1 entry","volume":"96","author":"Farzan","year":"1999","journal-title":"Cell"},{"key":"10.1016\/j.antiviral.2013.03.017_b0220","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1126\/science.272.5263.872","article-title":"HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor","volume":"272","author":"Feng","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.antiviral.2013.03.017_b0225","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.molcel.2010.02.012","article-title":"Topological layers in the HIV-1 gp120 inner domain regulate gp41 interaction and CD4-triggered conformational transitions","volume":"37","author":"Finzi","year":"2010","journal-title":"Mol. Cell"},{"key":"10.1016\/j.antiviral.2013.03.017_b1005","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1126\/scitranslmed.3001697","article-title":"Short-term monotherapy in HIV-infected patients with a virus entry inhibitor against the gp41 fusion peptide","volume":"2","author":"Forssmann","year":"2010","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.antiviral.2013.03.017_b0235","doi-asserted-by":"crossref","first-page":"3588","DOI":"10.1128\/JVI.71.5.3588-3596.1997","article-title":"Host-derived ICAM-1 glycoproteins incorporated on human immunodeficiency virus type 1 are biologically active and enhance viral infectivity","volume":"71","author":"Fortin","year":"1997","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2013.03.017_b0240","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1046\/j.1365-2249.2000.01348.x","article-title":"A single measurement of CD38CD8 cells in HIV+, long-term surviving injecting drug users distinguishes those who will progress to AIDS from those who will remain stable","volume":"122","author":"Froebel","year":"2000","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.antiviral.2013.03.017_b0245","doi-asserted-by":"crossref","first-page":"17706","DOI":"10.1073\/pnas.0805098105","article-title":"Highly potent, fully recombinant anti-HIV chemokines: reengineering a low-cost microbicide","volume":"105","author":"Gaertner","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.antiviral.2013.03.017_b0250","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/S0092-8674(00)80693-5","article-title":"Identification of DC-SIGN, a novel dendritic cell-specific ICAM-3 receptor that supports primary immune responses","volume":"100","author":"Geijtenbeek","year":"2000","journal-title":"Cell"},{"key":"10.1016\/j.antiviral.2013.03.017_b0255","first-page":"904","article-title":"Elevated levels of CD38+ CD8+ T cells in HIV infection add to the prognostic value of low CD4+ T cell levels: results of 6 years of follow-up. The Los Angeles Center, Multicenter AIDS Cohort Study","volume":"6","author":"Giorgi","year":"1993","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.antiviral.2013.03.017_b0260","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1128\/AAC.05857-11","article-title":"Correlation of the virological response to short-term maraviroc monotherapy with standard and deep-sequencing-based genotypic tropism prediction methods","volume":"56","author":"Gonzalez-Serna","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2013.03.017_b0265","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1086\/518797","article-title":"Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211","volume":"196","author":"Gulick","year":"2007","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2013.03.017_b0270","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/360358a0","article-title":"Inhibition of furin-mediated cleavage activation of HIV-1 glycoprotein gp160","volume":"360","author":"Hallenberger","year":"1992","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2013.03.017_b0275","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1097\/QAI.0b013e3181ee3d82","article-title":"Two-year safety and virologic efficacy of maraviroc in treatment-experienced patients with CCR5-tropic HIV-1 infection: 96-week combined analysis of MOTIVATE 1 and 2","volume":"55","author":"Hardy","year":"2010","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.antiviral.2013.03.017_b0280","doi-asserted-by":"crossref","first-page":"11126","DOI":"10.1074\/jbc.M800200200","article-title":"Design and evaluation of sifuvirtide, a novel HIV-1 fusion inhibitor","volume":"283","author":"He","year":"2008","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.antiviral.2013.03.017_b0285","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1097\/01.qai.0000137371.80695.ef","article-title":"Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection","volume":"37","author":"Hendrix","year":"2004","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.antiviral.2013.03.017_b0290","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1128\/AAC.06061-11","article-title":"Differential use of CCR5 by HIV-1 clinical isolates resistant to small-molecule CCR5 antagonists","volume":"56","author":"Henrich","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2013.03.017_b0295","doi-asserted-by":"crossref","first-page":"4017","DOI":"10.1128\/JVI.80.8.4017-4025.2006","article-title":"Envelope conformational changes induced by human immunodeficiency virus type 1 attachment inhibitors prevent CD4 binding and downstream entry events","volume":"80","author":"Ho","year":"2006","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2013.03.017_b0300","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/nbt.1663","article-title":"Human hematopoietic stem\/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo","volume":"28","author":"Holt","year":"2010","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.antiviral.2013.03.017_b0305","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1126\/science.1145373","article-title":"Structures of the CCR5 N terminus and of a tyrosine-sulfated antibody with HIV-1 gp120 and CD4","volume":"317","author":"Huang","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.antiviral.2013.03.017_b0310","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1126\/science.1118398","article-title":"Structure of a V3-containing HIV-1 gp120 core","volume":"310","author":"Huang","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.antiviral.2013.03.017_b0315","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1038\/nm1196-1240","article-title":"The role of a mutant CCR5 allele in HIV-1 transmission and disease progression","volume":"2","author":"Huang","year":"1996","journal-title":"Nat. Med."},{"key":"10.1016\/j.antiviral.2013.03.017_b0320","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1056\/NEJMoa0802905","article-title":"Long-term control of HIV by CCR5 Delta32\/Delta32 stem-cell transplantation","volume":"360","author":"H\u00fctter","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2013.03.017_b0325","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1093\/jac\/dkq432","article-title":"Efficacy and safety of nucleoside reverse transcriptase inhibitor-sparing salvage therapy for multidrug-resistant HIV-1 infection based on new-class and new-generation antiretrovirals","volume":"66","author":"Imaz","year":"2011","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.antiviral.2013.03.017_b0330","doi-asserted-by":"crossref","first-page":"e1001448","DOI":"10.1371\/journal.pbio.1001448","article-title":"Siglec-1 is a novel dendritic cell receptor that mediates HIV-1 trans-infection through recognition of viral membrane gangliosides","volume":"10","author":"Izquierdo-Useros","year":"2012","journal-title":"PLoS Biol."},{"key":"10.1016\/j.antiviral.2013.03.017_b0335","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1124\/mol.107.035055","article-title":"CCR5 small-molecule antagonists and monoclonal antibodies exert potent synergistic antiviral effects by cobinding to the receptor","volume":"72","author":"Ji","year":"2007","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.antiviral.2013.03.017_b0340","doi-asserted-by":"crossref","first-page":"10669","DOI":"10.1128\/JVI.05249-11","article-title":"Primary infection by a human immunodeficiency virus with atypical coreceptor tropism","volume":"85","author":"Jiang","year":"2011","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2013.03.017_b0345","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/365113a0","article-title":"HIV-1 inhibition by a peptide","volume":"365","author":"Jiang","year":"1993","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2013.03.017_b0350","doi-asserted-by":"crossref","first-page":"e46334","DOI":"10.1371\/journal.pone.0046334","article-title":"A genotypic test for HIV-1 tropism combining Sanger sequencing with ultradeep sequencing predicts virologic response in treatment-experienced patients","volume":"7","author":"Kagan","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.antiviral.2013.03.017_b0355","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1128\/JCM.32.2.364-370.1994","article-title":"MT-2 cell tropism as prognostic marker for disease progression in human immunodeficiency virus type 1 infection","volume":"32","author":"Karlsson","year":"1994","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.antiviral.2013.03.017_b0360","doi-asserted-by":"crossref","first-page":"11807","DOI":"10.1128\/JVI.78.21.11807-11815.2004","article-title":"Coevolution of RANTES sensitivity and mode of CCR5 receptor use by human immunodeficiency virus type 1 of the R5 phenotype","volume":"78","author":"Karlsson","year":"2004","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2013.03.017_b0365","unstructured":"Khanlou, H., Gathe, J., Schrader, S., Towner, W., Weinheimer, S., Lewis, S., 2011. Safety, efficacy, and pharmacokinetics of ibalizumab in treatment-experienced HIV-1 infected patiengs: a phase 2b study, in: Presented at the Program and Abstracts of the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy; Chicago, USA, September 17\u201320."},{"key":"10.1016\/j.antiviral.2013.03.017_b0370","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1089\/088922202760072294","article-title":"The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults","volume":"18","author":"Kilby","year":"2002","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"10.1016\/j.antiviral.2013.03.017_b0375","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1128\/AAC.01057-08","article-title":"Virologic failure in therapy-naive subjects on aplaviroc plus lopinavir-ritonavir: detection of aplaviroc resistance requires clonal analysis of envelope","volume":"53","author":"Kitrinos, K.M., Amrine-Madsen, H., Irlbeck, D.M., Word, J.M., Demarest, J.F., CCR100136 Study Team","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2013.03.017_b0380","first-page":"940","article-title":"Cenicriviroc, an orally active CCR5 antagonist for the potential treatment of HIV infection","volume":"11","author":"Klibanov","year":"2010","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"10.1016\/j.antiviral.2013.03.017_b0385","doi-asserted-by":"crossref","first-page":"e44827","DOI":"10.1371\/journal.pone.0044827","article-title":"Intercellular adhesion molecule 1 promotes HIV-1 attachment but not fusion to target cells","volume":"7","author":"Kondo","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.antiviral.2013.03.017_b0390","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1177\/135965350501000205","article-title":"Sensitivity of primary R5 HTV-1 to inhibition by RANTES correlates with sensitivity to small-molecule R5 inhibitors","volume":"10","author":"Koning","year":"2005","journal-title":"Antivir. Ther. (Lond)"},{"key":"10.1016\/j.antiviral.2013.03.017_b0395","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1086\/377105","article-title":"Decreasing sensitivity to RANTES (regulated on activation, normally T cell-expressed and -secreted) neutralization of CC chemokine receptor 5-using, non-syncytium-inducing virus variants in the course of human immunodeficiency virus type 1 infection","volume":"188","author":"Koning","year":"2003","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2013.03.017_b0400","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1128\/JVI.78.6.2790-2807.2004","article-title":"Genetic and phenotypic analyses of human immunodeficiency virus type 1 escape from a small-molecule CCR5 inhibitor","volume":"78","author":"Kuhmann","year":"2004","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2013.03.017_b0405","doi-asserted-by":"crossref","first-page":"5663","DOI":"10.1073\/pnas.1112391109","article-title":"Unliganded HIV-1 gp120 core structures assume the CD4-bound conformation with regulation by quaternary interactions and variable loops","volume":"109","author":"Kwon","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.antiviral.2013.03.017_b0410","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/31405","article-title":"Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody","volume":"393","author":"Kwong","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2013.03.017_b0415","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1097\/QAI.0b013e318213c2c0","article-title":"Safety, efficacy, and pharmacokinetics of TBR-652, a CCR5\/CCR2 antagonist, in HIV-1-infected, treatment-experienced, CCR5 antagonist-naive subjects","volume":"57","author":"Lalezari","year":"2011","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.antiviral.2013.03.017_b0420","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1097\/01.aids.0000183633.06580.8a","article-title":"Antiviral activity and safety of 873140, a novel CCR5 antagonist, during short-term monotherapy in HIV-infected adults","volume":"19","author":"Lalezari","year":"2005","journal-title":"AIDS"},{"key":"10.1016\/j.antiviral.2013.03.017_b0425","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1097\/00002030-200303280-00007","article-title":"A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy","volume":"17","author":"Lalezari","year":"2003","journal-title":"AIDS"},{"key":"10.1016\/j.antiviral.2013.03.017_b0430","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1126\/science.1099288","article-title":"Prevention of vaginal SHIV transmission in rhesus macaques through inhibition of CCR5","volume":"306","author":"Lederman","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.antiviral.2013.03.017_b0435","doi-asserted-by":"crossref","first-page":"9617","DOI":"10.1074\/jbc.274.14.9617","article-title":"Epitope mapping of CCR5 reveals multiple conformational states and distinct but overlapping structures involved in chemokine and coreceptor function","volume":"274","author":"Lee","year":"1999","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.antiviral.2013.03.017_b0440","doi-asserted-by":"crossref","first-page":"10373","DOI":"10.1016\/S0021-9258(18)86956-3","article-title":"Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the type 1 recombinant human immunodeficiency virus envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells","volume":"265","author":"Leonard","year":"1990","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.antiviral.2013.03.017_b0445","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1537-2995.2005.04222.x","article-title":"Augmented mobilization and collection of CD34+ hematopoietic cells from normal human volunteers stimulated with granulocyte-colony-stimulating factor by single-dose administration of AMD3100, a CXCR4 antagonist","volume":"45","author":"Liles","year":"2005","journal-title":"Transfusion"},{"key":"10.1016\/j.antiviral.2013.03.017_b0450","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1128\/JVI.77.2.931-942.2003","article-title":"Identification of gp120 binding sites on CXCR4 by using CD4-independent human immunodeficiency virus type 2 Env proteins","volume":"77","author":"Lin","year":"2003","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2013.03.017_b0455","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S0092-8674(00)80110-5","article-title":"Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection","volume":"86","author":"Liu","year":"1996","journal-title":"Cell"},{"key":"10.1016\/j.antiviral.2013.03.017_b0460","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1097\/00042560-199808010-00004","article-title":"CD8+ T-lymphocyte activation in HIV-1 disease reflects an aspect of pathogenesis distinct from viral burden and immunodeficiency. J","volume":"18","author":"Liu","year":"1998","journal-title":"Acquir. Immune Defic. Syndr. Hum. Retrovirol."},{"key":"10.1016\/j.antiviral.2013.03.017_b0465","doi-asserted-by":"crossref","first-page":"3277","DOI":"10.1074\/jbc.M110.199323","article-title":"In vitro selection and characterization of HIV-1 variants with increased resistance to sifuvirtide, a novel HIV-1 fusion inhibitor","volume":"286","author":"Liu","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.antiviral.2013.03.017_b0470","doi-asserted-by":"crossref","first-page":"6426","DOI":"10.1073\/pnas.94.12.6426","article-title":"Evolution of HIV-1 coreceptor usage through interactions with distinct CCR5 and CXCR4 domains","volume":"94","author":"Lu","year":"1997","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.antiviral.2013.03.017_b0475","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1097\/00002030-200006160-00012","article-title":"Strong association between failure of T cell homeostasis and the syncytium-inducing phenotype among HIV-1-infected men in the Amsterdam Cohort Study","volume":"14","author":"Maas","year":"2000","journal-title":"AIDS"},{"key":"10.1016\/j.antiviral.2013.03.017_b0480","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1310\/hct1201-24","article-title":"Maraviroc can improve lipid profiles in dyslipidemic patients with HIV: results from the MERIT trial","volume":"12","author":"MacInnes","year":"2011","journal-title":"HIV Clin. Trials"},{"key":"10.1016\/j.antiviral.2013.03.017_b0485","doi-asserted-by":"crossref","first-page":"3742","DOI":"10.1128\/JVI.78.7.3742-3752.2004","article-title":"Localized changes in the gp120 envelope glycoprotein confer resistance to human immunodeficiency virus entry inhibitors BMS-806 and #155","volume":"78","author":"Madani","year":"2004","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2013.03.017_b0490","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1128\/JVI.01764-08","article-title":"Estimating the stoichiometry of human immunodeficiency virus entry","volume":"83","author":"Magnus","year":"2009","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2013.03.017_b1010","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1089\/hum.2012.172","article-title":"Efficient Clinical Scale Gene Modification via Zinc Finger Nuclease-Targeted Disruption of the HIV Co-receptor CCR5","volume":"24","author":"Maier","year":"2013","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.antiviral.2013.03.017_b0500","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1128\/AAC.00713-10","article-title":"Pharmacokinetics and pharmacodynamics of TBR-652, a novel CCR5 antagonist, in HIV-1-infected, antiretroviral treatment-experienced, CCR5 antagonist-na\u00efve patients","volume":"55","author":"Marier","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2013.03.017_b0505","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/QAI.0b013e31826249cf","article-title":"Population-based sequencing of the V3-loop can predict the virological response to maraviroc in treatment-naive patients of the MERIT trial","volume":"61","author":"McGovern","year":"2012","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.antiviral.2013.03.017_b0510","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1086\/652189","article-title":"Characterization of emergent HIV resistance in treatment-naive subjects enrolled in a vicriviroc phase 2 trial","volume":"201","author":"McNicholas","year":"2010","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2013.03.017_b0515","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1086\/504693","article-title":"HIV-1 coreceptor use in triple-class treatment-experienced patients: baseline prevalence, correlates, and relationship to enfuvirtide response","volume":"194","author":"Melby","year":"2006","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2013.03.017_b0520","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1097\/QAD.0b013e3282f12362","article-title":"Association between specific enfuvirtide resistance mutations and CD4 cell response during enfuvirtide-based therapy","volume":"21","author":"Melby","year":"2007","journal-title":"AIDS"},{"key":"10.1016\/j.antiviral.2013.03.017_b0525","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/nm0397-338","article-title":"The role of viral phenotype and CCR-5 gene defects in HIV-1 transmission and disease progression","volume":"3","author":"Michael","year":"1997","journal-title":"Nat. Med."},{"key":"10.1016\/j.antiviral.2013.03.017_b0530","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1097\/QAI.0b013e31827b51b5","article-title":"Maraviroc once-daily nucleoside analog-sparing regimen in treatment-naive patients: randomized, open-label pilot study","volume":"62","author":"Mills","year":"2013","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.antiviral.2013.03.017_b0535","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.cell.2009.02.046","article-title":"HIV enters cells via endocytosis and dynamin-dependent fusion with endosomes","volume":"137","author":"Miyauchi","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.antiviral.2013.03.017_b0540","doi-asserted-by":"crossref","first-page":"3623","DOI":"10.1128\/JVI.72.5.3623-3634.1998","article-title":"Human immunodeficiency virus type 1 attachment to HeLa CD4 cells is CD4 independent and gp120 dependent and requires cell surface heparans","volume":"72","author":"Mondor","year":"1998","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2013.03.017_b0545","doi-asserted-by":"crossref","DOI":"10.1093\/jac\/dkt006","article-title":"Pharmacokinetic profile and safety of 150mg of maraviroc dosed with 800\/100mg of darunavir\/ritonavir all once daily, with and without nucleoside analogues, in HIV-infected subjects","author":"Mora-Peris","year":"2013","journal-title":"J. Antimicrob. Chemother"},{"key":"10.1016\/j.antiviral.2013.03.017_b0550","doi-asserted-by":"crossref","first-page":"3544","DOI":"10.1128\/JVI.73.5.3544-3550.1999","article-title":"Highly potent RANTES analogues either prevent CCR5-using human immunodeficiency virus type 1 infection in vivo or rapidly select for CXCR4-using variants","volume":"73","author":"Mosier","year":"1999","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2013.03.017_b0555","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1128\/JVI.74.4.1948-1960.2000","article-title":"Selective interactions of polyanions with basic surfaces on human immunodeficiency virus type 1 gp120","volume":"74","author":"Moulard","year":"2000","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2013.03.017_b0560","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1086\/597097","article-title":"Proof of activity with AMD11070, an orally bioavailable inhibitor of CXCR4-tropic HIV type 1","volume":"48","author":"Moyle","year":"2009","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.antiviral.2013.03.017_b0565","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.cell.2007.02.042","article-title":"Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide","volume":"129","author":"M\u00fcnch","year":"2007","journal-title":"Cell"},{"key":"10.1016\/j.antiviral.2013.03.017_b0570","doi-asserted-by":"crossref","first-page":"6089","DOI":"10.1128\/JVI.73.7.6089-6092.1999","article-title":"Role of the membrane-proximal domain in the initial stages of human immunodeficiency virus type 1 envelope glycoprotein-mediated membrane fusion","volume":"73","author":"Mu\u00f1oz-Barroso","year":"1999","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2013.03.017_b0575","doi-asserted-by":"crossref","first-page":"e1001301","DOI":"10.1371\/journal.ppat.1001301","article-title":"The genotype of early-transmitting HIV gp120s promotes \u03b1 (4) \u03b2(7)-reactivity, revealing \u03b1 (4) \u03b2(7) +\/CD4+ T cells as key targets in mucosal transmission","volume":"7","author":"Nawaz","year":"2011","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.antiviral.2013.03.017_b0580","doi-asserted-by":"crossref","first-page":"5842","DOI":"10.1128\/JVI.01907-09","article-title":"\u201cResistance\u201d to PSC-RANTES revisited: two mutations in human immunodeficiency virus type 1 HIV-1 SF162 or simian-human immunodeficiency virus SHIV SF162-p3 do not confer resistance","volume":"84","author":"Nedellec","year":"2010","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2013.03.017_b0585","doi-asserted-by":"crossref","first-page":"e22020","DOI":"10.1371\/journal.pone.0022020","article-title":"Resistance to the CCR5 inhibitor 5P12-RANTES requires a difficult evolution from CCR5 to CXCR4 coreceptor use","volume":"6","author":"Nedellec","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.antiviral.2013.03.017_b0590","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1093\/infdis\/jis432","article-title":"Pharmacodynamics, safety, and pharmacokinetics of BMS-663068, an oral HIV-1 attachment inhibitor in HIV-1-infected subjects","volume":"206","author":"Nettles","year":"2012","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2013.03.017_b0595","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1128\/AAC.00821-07","article-title":"Hepatotoxicity observed in clinical trials of aplaviroc (GW873140)","volume":"52","author":"Nichols","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2013.03.017_b0600","doi-asserted-by":"crossref","first-page":"3498","DOI":"10.1128\/AAC.00426-12","article-title":"In vitro antiviral characteristics of HIV-1 attachment inhibitor BMS-626529, the active component of the prodrug BMS-663068","volume":"56","author":"Nowicka-Sans","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2013.03.017_b0605","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1038\/382833a0","article-title":"The CXC chemokine SDF-1 is the ligand for LESTR\/fusin and prevents infection by T-cell-line-adapted HIV-1","volume":"382","author":"Oberlin","year":"1996","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2013.03.017_b0610","series-title":"Mapping resistance to the CCR5 co-receptor antagonist vicriviroc using heterologous chimeric HIV-1 envelope genes reveals key determinants in the C2\u2013V5 domain of gp120","author":"Ogert","year":"2008"},{"key":"10.1016\/j.antiviral.2013.03.017_b0615","doi-asserted-by":"crossref","first-page":"12151","DOI":"10.1128\/JVI.01351-09","article-title":"Structure-function analysis of human immunodeficiency virus type 1 gp120 amino acid mutations associated with resistance to the CCR5 coreceptor antagonist vicriviroc","volume":"83","author":"Ogert","year":"2009","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2013.03.017_b0620","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/QAI.0b013e3182732746","article-title":"Anti-CD4 monoclonal antibody ibalizumab exhibits breadth and potency against HIV-1, with natural resistance mediated by the loss of a V5 glycan in envelope","volume":"62","author":"Pace","year":"2013","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.antiviral.2013.03.017_b0625","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1128\/JVI.02964-12","article-title":"Transmitted\/Founder and Chronic HIV-1 Envelope Proteins Are Distinguished by Differential Utilization of CCR5","volume":"87","author":"Parker","year":"2013","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2013.03.017_b0630","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1038\/nbt1410","article-title":"Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases","volume":"26","author":"Perez","year":"2008","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.antiviral.2013.03.017_b0635","doi-asserted-by":"crossref","first-page":"32017","DOI":"10.1074\/jbc.M112.343293","article-title":"Trans-infection but not infection from within endosomal compartments after cell-to-cell HIV-1 transfer to CD4+ T cells","volume":"287","author":"Permanyer","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.antiviral.2013.03.017_b0640","doi-asserted-by":"crossref","first-page":"6505","DOI":"10.1128\/JVI.00374-10","article-title":"HIV-1 resistance to CCR5 antagonists associated with highly efficient use of CCR5 and altered tropism on primary CD4+ T cells","volume":"84","author":"Pfaff","year":"2010","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2013.03.017_b0645","doi-asserted-by":"crossref","first-page":"12266","DOI":"10.1128\/JVI.75.24.12266-12278.2001","article-title":"Adaptive mutations in the V3 loop of gp120 enhance fusogenicity of human immunodeficiency virus type 1 and enable use of a CCR5 coreceptor that lacks the amino-terminal sulfated region","volume":"75","author":"Platt","year":"2001","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2013.03.017_b0650","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/jmv.20141","article-title":"Evolution of genotypic and phenotypic resistance to Enfuvirtide in HIV-infected patients experiencing prolonged virologic failure","volume":"74","author":"Poveda","year":"2004","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.antiviral.2013.03.017_b0655","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.virol.2006.11.004","article-title":"HIV-1 clones resistant to a small molecule CCR5 inhibitor use the inhibitor-bound form of CCR5 for entry","volume":"361","author":"Pugach","year":"2007","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2013.03.017_b0660","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.virol.2009.02.044","article-title":"Inefficient entry of vicriviroc-resistant HIV-1 via the inhibitor-CCR5 complex at low cell surface CCR5 densities","volume":"387","author":"Pugach","year":"2009","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2013.03.017_b0665","doi-asserted-by":"crossref","first-page":"7475","DOI":"10.1073\/pnas.1201104109","article-title":"HIV-1 incorporation of host-cell-derived glycosphingolipid GM3 allows for capture by mature dendritic cells","volume":"109","author":"Puryear","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.antiviral.2013.03.017_b0670","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1128\/JVI.06421-11","article-title":"HIV-1 clinical isolates resistant to CCR5 antagonists exhibit delayed entry kinetics that are corrected in the presence of drug","volume":"86","author":"Putcharoen","year":"2012","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2013.03.017_b0675","doi-asserted-by":"crossref","first-page":"3464","DOI":"10.1128\/JVI.72.4.3464-3468.1998","article-title":"Alanine substitutions of polar and nonpolar residues in the amino-terminal domain of CCR5 differently impair entry of macrophage- and dualtropic isolates of human immunodeficiency virus type 1","volume":"72","author":"Rabut","year":"1998","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2013.03.017_b0680","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/S0140-6736(05)62697-9","article-title":"32 bp CCR-5 gene deletion and resistance to fast progression in HIV-1 infected heterozygotes","volume":"349","author":"Rappaport","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.antiviral.2013.03.017_b0685","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1128\/JVI.01863-12","article-title":"HIV-1 resistance to maraviroc conferred by a CD4 binding site mutation in the envelope glycoprotein gp120","volume":"87","author":"Ratcliff","year":"2013","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2013.03.017_b0690","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1128\/JVI.02496-08","article-title":"HR-2 mutations in human immunodeficiency virus type 1 gp41 restore fusion kinetics delayed by HR-1 mutations that cause clinical resistance to enfuvirtide","volume":"83","author":"Ray","year":"2009","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2013.03.017_b0695","doi-asserted-by":"crossref","first-page":"3240","DOI":"10.1128\/JVI.02413-06","article-title":"Clinical resistance to enfuvirtide does not affect susceptibility of human immunodeficiency virus type 1 to other classes of entry inhibitors","volume":"81","author":"Ray","year":"2007","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2013.03.017_b0700","doi-asserted-by":"crossref","first-page":"16249","DOI":"10.1073\/pnas.252469399","article-title":"Sensitivity of HIV-1 to entry inhibitors correlates with envelope\/coreceptor affinity, receptor density, and fusion kinetics","volume":"99","author":"Reeves","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.antiviral.2013.03.017_b0705","doi-asserted-by":"crossref","first-page":"4991","DOI":"10.1128\/JVI.79.8.4991-4999.2005","article-title":"Enfuvirtide resistance mutations: impact on human immunodeficiency virus envelope function, entry inhibitor sensitivity, and virus neutralization","volume":"79","author":"Reeves","year":"2005","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2013.03.017_b0710","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1099\/vir.0.81111-0","article-title":"Selection of human immunodeficiency virus type 1 R5 variants with augmented replicative capacity and reduced sensitivity to entry inhibitors during severe immunodeficiency","volume":"86","author":"Repits","year":"2005","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.antiviral.2013.03.017_b0715","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1056\/NEJMoa1201248","article-title":"Blockade of lymphocyte chemotaxis in visceral graft-versus-host disease","volume":"367","author":"Reshef","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2013.03.017_b0720","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1186\/2047-783X-15-6-231","article-title":"Maraviroc in treatment-experienced patients with HIV-1 infection - experience from routine clinical practice","volume":"15","author":"Reuter","year":"2010","journal-title":"Eur. J. Med. Res."},{"key":"10.1016\/j.antiviral.2013.03.017_b0725","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1093\/infdis\/169.5.968","article-title":"The impact of the syncytium-inducing phenotype of human immunodeficiency virus on disease progression","volume":"169","author":"Richman","year":"1994","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2013.03.017_b0730","doi-asserted-by":"crossref","first-page":"4330","DOI":"10.1128\/JVI.00106-11","article-title":"HIV-1 escape from the CCR5 antagonist maraviroc associated with an altered and less-efficient mechanism of gp120-CCR5 engagement that attenuates macrophage tropism","volume":"85","author":"Roche","year":"2011","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2013.03.017_b0735","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1086\/598965","article-title":"A double-blind, placebo-controlled trial of maraviroc in treatment-experienced patients infected with non-R5 HIV-1","volume":"199","author":"Saag","year":"2009","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2013.03.017_b0740","doi-asserted-by":"crossref","first-page":"24934","DOI":"10.1074\/jbc.272.40.24934","article-title":"The second extracellular loop of CCR5 is the major determinant of ligand specificity","volume":"272","author":"Samson","year":"1997","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.antiviral.2013.03.017_b0745","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/382722a0","article-title":"Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene","volume":"382","author":"Samson","year":"1996","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2013.03.017_b0750","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1093\/infdis\/jiq118","article-title":"Plasma levels of soluble CD14 independently predict mortality in HIV infection","volume":"203","author":"Sandler","year":"2011","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2013.03.017_b0755","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1038\/nm1197-1259","article-title":"In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression","volume":"3","author":"Scarlatti","year":"1997","journal-title":"Nat. Med."},{"key":"10.1016\/j.antiviral.2013.03.017_b0760","doi-asserted-by":"crossref","first-page":"395","DOI":"10.3851\/IMP1759","article-title":"Baseline CD4(+) T-cell counts and weighted background susceptibility scores strongly predict response to maraviroc regimens in treatment-experienced patients","volume":"16","author":"Schapiro","year":"2011","journal-title":"Antivir. Ther. (Lond)"},{"key":"10.1016\/j.antiviral.2013.03.017_b0765","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1128\/JVI.66.3.1354-1360.1992","article-title":"Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population","volume":"66","author":"Schuitemaker","year":"1992","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2013.03.017_b0770","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1126\/science.276.5310.276","article-title":"Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist","volume":"276","author":"Simmons","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.antiviral.2013.03.017_b0775","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1016\/j.bmcl.2011.01.021","article-title":"Design of novel CXCR4 antagonists that are potent inhibitors of T-tropic (X4) HIV-1 replication","volume":"21","author":"Skerlj","year":"2011","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.antiviral.2013.03.017_b0780","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.bmcl.2010.11.023","article-title":"Synthesis and SAR of novel CXCR4 antagonists that are potent inhibitors of T tropic (X4) HIV-1 replication","volume":"21","author":"Skerlj","year":"2011","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.antiviral.2013.03.017_b0785","doi-asserted-by":"crossref","first-page":"6935","DOI":"10.1128\/JVI.00453-10","article-title":"Epitope mapping of ibalizumab, a humanized anti-CD4 monoclonal antibody with anti-HIV-1 activity in infected patients","volume":"84","author":"Song","year":"2010","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2013.03.017_b0790","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1002\/jmv.21138","article-title":"Unexpected dramatic increase in CD4+ cell count in a patient with AIDS after enfuvirtide treatment despite persistent viremia and resistance mutations","volume":"80","author":"Soria","year":"2008","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.antiviral.2013.03.017_b0795","doi-asserted-by":"crossref","first-page":"e63","DOI":"10.1371\/journal.ppat.0030063","article-title":"Electron tomography of the contact between T cells and SIV\/HIV-1: implications for viral entry","volume":"3","author":"Sougrat","year":"2007","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.antiviral.2013.03.017_b0800","doi-asserted-by":"crossref","DOI":"10.1093\/jac\/dkt018","article-title":"Frequency of amino acid changes associated with resistance to attachment inhibitor BMS-626529 in R5- and X4-tropic HIV-1 subtype B","author":"Souli\u00e9","year":"2013","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.antiviral.2013.03.017_b0805","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/0092-8674(86)90778-6","article-title":"Identification and characterization of conserved and variable regions in the envelope gene of HTLV-III\/LAV, the retrovirus of AIDS","volume":"45","author":"Starcich","year":"1986","journal-title":"Cell"},{"key":"10.1016\/j.antiviral.2013.03.017_b0810","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1128\/AAC.00013-07","article-title":"Multiple-dose escalation study of the safety, pharmacokinetics, and biologic activity of oral AMD070, a selective CXCR4 receptor inhibitor, in human subjects","volume":"51","author":"Stone","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2013.03.017_b0815","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1056\/NEJMoa062360","article-title":"CD4+ count-guided interruption of antiretroviral treatment","volume":"355","author":"Strategies for Management of Antiretroviral Therapy (SMART) Study Group","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2013.03.017_b0820","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/cit105","article-title":"Use of cellular HIV DNA to predict virologic response to maraviroc: performance of population-based and deep sequencing","author":"Swenson","year":"2013","journal-title":"Clin. Infect Dis."},{"key":"10.1016\/j.antiviral.2013.03.017_b0825","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1093\/cid\/cir493","article-title":"Deep V3 sequencing for HIV type 1 tropism in treatment-naive patients: a reanalysis of the MERIT trial of maraviroc","volume":"53","author":"Swenson","year":"2011","journal-title":"Clin. Infect Dis."},{"key":"10.1016\/j.antiviral.2013.03.017_b0830","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1089\/aid.2009.0132","article-title":"HIV type 1 from a patient with baseline resistance to CCR5 antagonists uses drug-bound receptor for entry","volume":"26","author":"Tilton","year":"2010","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"10.1016\/j.antiviral.2013.03.017_b0835","doi-asserted-by":"crossref","first-page":"10863","DOI":"10.1128\/JVI.01109-10","article-title":"A maraviroc-resistant HIV-1 with narrow cross-resistance to other CCR5 antagonists depends on both N-terminal and extracellular loop domains of drug-bound CCR5","volume":"84","author":"Tilton","year":"2010","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2013.03.017_b0840","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1097\/00126334-200010010-00001","article-title":"Strong in vitro synergy between the fusion inhibitor T-20 and the CXCR4 blocker AMD-3100","volume":"25","author":"Tremblay","year":"2000","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.antiviral.2013.03.017_b0845","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/384184a0","article-title":"CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5","volume":"384","author":"Trkola","year":"1996","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2013.03.017_b0850","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1073\/pnas.012519099","article-title":"HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use","volume":"99","author":"Trkola","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.antiviral.2013.03.017_b0855","doi-asserted-by":"crossref","first-page":"6416","DOI":"10.1128\/JVI.00286-12","article-title":"Vicriviroc resistance decay and relative replicative fitness in HIV-1 clinical isolates under sequential drug selection pressures","volume":"86","author":"Tsibris","year":"2012","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2013.03.017_b0860","doi-asserted-by":"crossref","first-page":"e28047","DOI":"10.1371\/journal.pone.0028047","article-title":"SHIV-162P3 infection of rhesus macaques given maraviroc gel vaginally does not involve resistant viruses","volume":"6","author":"Tsibris","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.antiviral.2013.03.017_b0865","doi-asserted-by":"crossref","first-page":"8210","DOI":"10.1128\/JVI.00444-08","article-title":"In vivo emergence of vicriviroc resistance in a human immunodeficiency virus type 1 subtype C-infected subject","volume":"82","author":"Tsibris","year":"2008","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2013.03.017_b0870","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1086\/655661","article-title":"Protection of rhesus macaques from vaginal infection by vaginally delivered maraviroc, an inhibitor of HIV-1 entry via the CCR5 co-receptor","volume":"202","author":"Veazey","year":"2010","journal-title":"J. Infect Dis."},{"key":"10.1016\/j.antiviral.2013.03.017_b0875","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/nature04055","article-title":"Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus-cell fusion","volume":"438","author":"Veazey","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2013.03.017_b0880","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1086\/598685","article-title":"Topically applied recombinant chemokine analogues fully protect macaques from vaginal simian-human immunodeficiency virus challenge","volume":"199","author":"Veazey","year":"2009","journal-title":"J. Infect Dis."},{"key":"10.1016\/j.antiviral.2013.03.017_b0885","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1038\/mt.2012.284","article-title":"Generation of an HIV Resistant T-cell Line by Targeted \u201cStacking\u201d of Restriction Factors","volume":"21","author":"Voit","year":"2013","journal-title":"Mol. Ther."},{"key":"10.1016\/j.antiviral.2013.03.017_b0890","doi-asserted-by":"crossref","first-page":"10799","DOI":"10.1073\/pnas.191124098","article-title":"Crystal structure of the human CD4 N-terminal two-domain fragment complexed to a class II MHC molecule","volume":"98","author":"Wang","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.antiviral.2013.03.017_b0895","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1128\/AAC.46.6.1896-1905.2002","article-title":"Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy","volume":"46","author":"Wei","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2013.03.017_b0900","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1093\/jac\/dks341","article-title":"Response to raltegravir-based salvage therapy in HIV-infected patients with hepatitis C virus or hepatitis B virus coinfection","volume":"68","author":"Weimer","year":"2013","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.antiviral.2013.03.017_b0905","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/387426a0","article-title":"Atomic structure of the ectodomain from HIV-1 gp41","volume":"387","author":"Weissenhorn","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2013.03.017_b0910","doi-asserted-by":"crossref","first-page":"16828","DOI":"10.1073\/pnas.0708109104","article-title":"Potent D-peptide inhibitors of HIV-1 entry","volume":"104","author":"Welch","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.antiviral.2013.03.017_b0915","doi-asserted-by":"crossref","first-page":"4909","DOI":"10.1128\/JVI.80.10.4909-4920.2006","article-title":"Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir","volume":"80","author":"Westby","year":"2006","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2013.03.017_b0920","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1128\/JVI.02006-06","article-title":"Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry","volume":"81","author":"Westby","year":"2007","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2013.03.017_b0925","doi-asserted-by":"crossref","first-page":"10537","DOI":"10.1073\/pnas.89.21.10537","article-title":"A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition","volume":"89","author":"Wild","year":"1992","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.antiviral.2013.03.017_b0930","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/978-1-4614-0980-9_10","article-title":"Molecular mechanisms of HIV entry","volume":"726","author":"Wilen","year":"2012","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.antiviral.2013.03.017_b0935","doi-asserted-by":"crossref","first-page":"e1002020","DOI":"10.1371\/journal.ppat.1002020","article-title":"Engineering HIV-Resistant Human CD4+ T Cells with CXCR4-Specific Zinc-Finger Nucleases","volume":"7","author":"Wilen","year":"2011","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.antiviral.2013.03.017_b0940","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1093\/infdis\/jis376","article-title":"A pilot trial of adding maraviroc to suppressive antiretroviral therapy for suboptimal CD4 T-cell recovery despite sustained virologic suppression: ACTG A5256","volume":"206","author":"Wilkin","year":"2012","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2013.03.017_b0945","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1089\/aid.2012.0157","article-title":"Maraviroc observational study: the impact of expanded resistance testing and clinical considerations for antiretroviral regimen selection in treatment-experienced patients","volume":"29","author":"Willig","year":"2013","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"10.1016\/j.antiviral.2013.03.017_b0950","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/384179a0","article-title":"CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5","volume":"384","author":"Wu","year":"1996","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2013.03.017_b0955","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1084\/jem.186.8.1373","article-title":"Interaction of chemokine receptor CCR5 with its ligands: multiple domains for HIV-1 gp120 binding and a single domain for chemokine binding","volume":"186","author":"Wu","year":"1997","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.antiviral.2013.03.017_b0960","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1038\/31514","article-title":"The antigenic structure of the HIV gp120 envelope glycoprotein","volume":"393","author":"Wyatt","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2013.03.017_b0965","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1128\/AAC.49.3.1113-1119.2005","article-title":"Emergence and evolution of enfuvirtide resistance following long-term therapy involves heptad repeat 2 mutations within gp41","volume":"49","author":"Xu","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2013.03.017_b0970","doi-asserted-by":"crossref","first-page":"12132","DOI":"10.1128\/JVI.79.19.12132-12147.2005","article-title":"Stoichiometry of envelope glycoprotein trimers in the entry of human immunodeficiency virus type 1","volume":"79","author":"Yang","year":"2005","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2013.03.017_b0975","doi-asserted-by":"crossref","first-page":"4388","DOI":"10.1128\/JVI.80.9.4388-4395.2006","article-title":"Subunit stoichiometry of human immunodeficiency virus type 1 envelope glycoprotein trimers during virus entry into host cells","volume":"80","author":"Yang","year":"2006","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2013.03.017_b0980","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.virol.2011.02.019","article-title":"A combination of polymorphic mutations in V3 loop of HIV-1 gp120 can confer noncompetitive resistance to maraviroc","volume":"413","author":"Yuan","year":"2011","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2013.03.017_b0985","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.1371\/journal.ppat.0020083","article-title":"Cryo-electron tomographic structure of an immunodeficiency virus envelope complex in situ","volume":"2","author":"Zanetti","year":"2006","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.antiviral.2013.03.017_b0990","doi-asserted-by":"crossref","first-page":"15812","DOI":"10.1073\/pnas.2634931100","article-title":"Electron tomography analysis of envelope glycoprotein trimers on HIV and simian immunodeficiency virus virions","volume":"100","author":"Zhu","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.antiviral.2013.03.017_b0995","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1038\/nature04817","article-title":"Distribution and three-dimensional structure of AIDS virus envelope spikes","volume":"441","author":"Zhu","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2013.03.017_b1000","doi-asserted-by":"crossref","first-page":"e1000203","DOI":"10.1371\/journal.ppat.1000203","article-title":"Cryoelectron tomography of HIV-1 envelope spikes: further evidence for tripod-like legs","volume":"4","author":"Zhu","year":"2008","journal-title":"PLoS Pathog."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354213000715?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354213000715?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,6,30]],"date-time":"2023-06-30T18:07:11Z","timestamp":1688148431000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354213000715"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5]]},"references-count":200,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,5]]}},"alternative-id":["S0166354213000715"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2013.03.017","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2013,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Entry inhibitors and their use in the treatment of HIV-1 infection","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2013.03.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}